BioLineRx, Ltd. (NASDAQ:BLRX) Q3 2018 Earnings Conference Call - Final Transcript
Nov 07, 2018 • 07:00 pm ET
Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2018 Conference Call. All participants are present in a listen-only mode. Following the management's formal presentation, instructions will be given for the question-and-answer session.
I would now like to turn over the call to Timothy McCarthy of LifeSci Advisors to read the Safe Harbor statement. Tim, please go ahead.
Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call other than historical facts are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project or other similar expressions are used typically to identify such forward-looking statements.
These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial condition and other operating results. These include, but are not limited to the risk factors and other qualifications contained in BioLineRx's annual report on Form 20-F, quarterly reports filed in our 6-K and other reports filed by BioLineRx with the SEC to which your attention is directed.
Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. BioLineRx expressly disclaims any intent or obligation to update these forward-looking statements.
At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx. Phil?
Thank you, Tim, and good morning everyone. And thank you for joining us on our third quarter earnings conference call today. Earlier this morning, we issued our Q3 earnings press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a 6-K.
Our agenda this morning is as follows. We will begin with a review of our programs and activities, enumerate our major target milestones over the next few quarters and then Mali Zeevi, our Chief Financial Officer will provide a short discussion of our financial results. We will then open up the call to your questions. Also joining the call for Q&A are Abi Vainstein, Vice President, Clinical and Medical Affairs, Ella Sorani, Vice President, Research and Development and Hillit Shachar, our Vice President, Business Development.
During the third quarter, we took a number of steps to strengthen and advance both of our oncology programs while positioning our Company for long-term success and we are excited for the opportunity to provide an update in this regard.
Let's begin with Bl-8040 our elite and most advanced program. For those of you who may be new to the BioLineRx story, BL-8040 is a novel short peptide that functions as a high-affinity antagonist to CXCR-4, a chemokine receptor, whose over expression has been implicated in the progression of over 70% of all cancers. We are evaluating BL-8040 in eight Phase 2 or Phase 3 clinical trials in multiple oncology indications including stem